Trius Therapeutics Secures $25M Equity Financing
Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that it has obtained a committed equity financing facility under which it may from time to time sell up to $25 million of its registered common stock to Terrapin Opportunity, L.P., over a 24-month period. Trius is not obligated to utilize any of the $25 million facility and remains free to enter into and consummate other equity and debt financing transactions, subject to certain restrictions.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.